See more : Yuhwa Securities co.,ltd. (003465.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Generation Bio Co. (GBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Generation Bio Co., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SMC Entertainment, Inc. (SMCE) Income Statement Analysis – Financial Results
- Mongolian Mining Corporation (MOGLF) Income Statement Analysis – Financial Results
- Literacy Capital plc (BOOK.L) Income Statement Analysis – Financial Results
- Ramelius Resources Limited (RMLRF) Income Statement Analysis – Financial Results
- Amazing Microelectronic Corp. (6411.TWO) Income Statement Analysis – Financial Results
Generation Bio Co. (GBIO)
About Generation Bio Co.
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 5.90M | 0.00 | 0.00 | 0.00 | 0.00 | 36.00K |
| Cost of Revenue | 79.82M | 5.13M | 4.53M | 3.43M | 1.86M | 0.00 |
| Gross Profit | -73.91M | -5.13M | -4.53M | -3.43M | -1.86M | 36.00K |
| Gross Profit Ratio | -1,251.88% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 93.62M | 96.72M | 85.25M | 58.53M | 50.13M | 28.15M |
| General & Administrative | 50.85M | 44.46M | 33.85M | 22.58M | 12.17M | 9.18M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.85M | 44.46M | 33.85M | 22.58M | 12.17M | 9.18M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 144.47M | 141.18M | 119.10M | 81.11M | 62.30M | 37.33M |
| Cost & Expenses | 144.47M | 141.18M | 119.10M | 81.11M | 62.30M | 37.33M |
| Interest Income | 11.95M | 4.54M | 187.00K | 591.00K | 975.00K | 0.00 |
| Interest Expense | 0.00 | 4.54M | 50.00K | 591.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.26M | 5.13M | 4.53M | 3.43M | 1.86M | 347.00K |
| EBITDA | -133.30M | -136.05M | -114.57M | -77.68M | -60.44M | -36.95M |
| EBITDA Ratio | -2,257.79% | 0.00% | 0.00% | 0.00% | 0.00% | -102,630.56% |
| Operating Income | -138.56M | -141.18M | -119.10M | -81.11M | -62.30M | -37.29M |
| Operating Income Ratio | -2,346.93% | 0.00% | 0.00% | 0.00% | 0.00% | -103,594.44% |
| Total Other Income/Expenses | 11.95M | 4.54M | -50.00K | 591.00K | 985.00K | 1.49M |
| Income Before Tax | -126.61M | -136.64M | -119.15M | -80.52M | -61.32M | -35.80M |
| Income Before Tax Ratio | -2,144.51% | 0.00% | 0.00% | 0.00% | 0.00% | -99,452.78% |
| Income Tax Expense | 0.00 | -4.54M | -4.48M | -4.02M | -985.00K | 1.49M |
| Net Income | -126.61M | -132.10M | -114.67M | -76.50M | -60.33M | -35.80M |
| Net Income Ratio | -2,144.51% | 0.00% | 0.00% | 0.00% | 0.00% | -99,452.78% |
| EPS | -1.96 | -2.27 | -2.04 | -2.81 | -1.31 | -1.82 |
| EPS Diluted | -1.96 | -2.27 | -2.04 | -2.81 | -1.31 | -1.82 |
| Weighted Avg Shares Out | 64.48M | 58.11M | 56.30M | 27.26M | 46.21M | 19.69M |
| Weighted Avg Shares Out (Dil) | 64.48M | 58.11M | 56.30M | 27.26M | 46.21M | 19.69M |
Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.43 per share a year ago.
Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress
CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented data on its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms...
Generation Bio to Present at the 2024 Cantor Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a...
Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.47 per share a year ago.
Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a...
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a...
Cofi.ai Names Aaron Kizer President and Equity Partner
AUSTIN, TX/ ACCESSWIRE / May 20, 2024 / Cofi.ai, a groundbreaking financial planning and analysis software built for VC/PE and SMB tech companies, announced today that Aaron Kizer has joined the company as President. As the company continues to accelerate...
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
Generation Bio Co. (GBIO) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.53 per share a year ago.
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
- Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP)
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented five posters on its immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle...
Source: https://incomestatements.info
Category: Stock Reports